Cargando…
Role of prolactin receptor and CD25 in protection of circulating T lymphocytes from apoptosis in patients with breast cancer
Prolactin (PRL) has been reported to inhibit apoptosis in various cell types and to serve as a cofactor in the upregulation of CD25 on T cells during activation. We investigated a possible relation between prolactin receptor (PRL-R) or IL-2 receptor alpha (IL-2Rα, CD25) expression on circulating T l...
Autores principales: | Bauernhofer, T, Kuss, I, Friebe-Hoffmann, U, Baum, A S, Dworacki, G, Vonderhaar, B K, Whiteside, T L |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2747567/ https://www.ncbi.nlm.nih.gov/pubmed/12698200 http://dx.doi.org/10.1038/sj.bjc.6600860 |
Ejemplares similares
-
Spontaneous apoptosis of circulating T-lymphocytes and its correlation to their prolactin receptor expression and prolactin plasma levels in patients with breast cancer
por: Bauernhofer, T, et al.
Publicado: (2001) -
The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer
por: Horlock, C, et al.
Publicado: (2009) -
Prolactin receptor is a negative prognostic factor in patients with squamous cell carcinoma of the head and neck
por: Bauernhofer, T, et al.
Publicado: (2011) -
CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors
por: Sato, K, et al.
Publicado: (2003) -
Alterations of the expression of T-cell-related costimulatory CD28 and downregulatory CD152 (CTLA-4) molecules in patients with B-cell chronic lymphocytic leukaemia
por: Frydecka, I, et al.
Publicado: (2004)